In this randomized, double-blind, phase II study, 135 previously untreated patients with advanced NSCLC positive for PD-L1 expression (≥1%) were randomized to receive tiragolumab plus atezolizumab or placebo plus atezolizumab as first-line treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.